Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide

Scott D. Putney, Josiah Brown, Carla Cucco, Rino Lee, Tomasz Skorski, Carlo Leonetti, Timothy Geiser, Bruno Calabretta, Gabriella Zupi, Gerald Zon

Research output: Contribution to journalArticle

Abstract

A phosphorothioate c-myc antisense oligonucleotide was complexed with zinc and encapsulated into injectable biodegradable microspheres. The efficacy of this novel formulation was compared with intravenous administration of the unencapsulated drug in human melanoma and leukemia xenografts in immunocompromised mice. The microencapsulated formulation was more effective as shown by reduced tumor growth, a decreased number of metastases, reduced c-myc expression, and increased survival in the melanoma model, and decreased metastatic potential and increased survival in the leukemia model. These results show that, as has been demonstrated previously with protein and peptide drugs, greater therapeutic efficacy can be obtained when antisense oligonucleotides are delivered from sustained-release formulations.

Original languageEnglish
Pages (from-to)451-458
Number of pages8
JournalAntisense and Nucleic Acid Drug Development
Volume9
Issue number5
Publication statusPublished - 1999

    Fingerprint

ASJC Scopus subject areas

  • Genetics
  • Pharmacology

Cite this

Putney, S. D., Brown, J., Cucco, C., Lee, R., Skorski, T., Leonetti, C., Geiser, T., Calabretta, B., Zupi, G., & Zon, G. (1999). Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. Antisense and Nucleic Acid Drug Development, 9(5), 451-458.